Announcements Trials
Browse Landscape

Status

Completed 4

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 376Observational 4

Sponsor

Cancer Type

CNS 4

Conditions

Breast Neoplasms 112Neoplasms 73Carcinoma, Non-Small-Cell Lung 36Carcinoma, Renal Cell 35Prostatic Neoplasms 34Colorectal Neoplasms 34Lung Neoplasms 31Melanoma 17Multiple Myeloma 15Ovarian Neoplasms 13Urinary Bladder Neoplasms 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Neoplasm Metastasis 11Lymphoma, Follicular 11Colonic Neoplasms 11Stomach Neoplasms 10Lymphoma 10Kidney Neoplasms 10Hematologic Neoplasms 10Rectal Neoplasms 9Arthritis, Rheumatoid 9Recurrence 8Papillomavirus Infections 8Leukemia, Myeloid, Acute 8Carcinoma, Hepatocellular 8Pancreatic Neoplasms 7Neoplasms, Plasma Cell 7Lymphoma, Large B-Cell, Diffuse 7COVID-19 7Leukemia, Lymphocytic, Chronic, B-Cell 6

Interventions

Temozolomide 3Radiotherapy 3Radiation 3Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Observational × Has results × Glioblastoma × Clear all
NCT02060890 2023-12-12

TGEN

University of California, San Francisco

Completed
20 enrolled 11 charts
CNS

Glioblastoma

NCT00704808 2015-09-09

Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)

Merck Sharp & Dohme LLC

Completed
180 enrolled 6 charts
CNS

Glioblastoma

NCT00725010 2015-09-09

Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816)

Merck Sharp & Dohme LLC

Completed
64 enrolled 7 charts
CNS

Glioblastoma

NCT00723827 2015-01-30

Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)

Merck Sharp & Dohme LLC

Completed
682 enrolled 10 charts
CNS

Astrocytoma, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡